Biotech News

Elutia Reports Third Quarter 2026 Results: As Plastic Surgeons Cite Infection Risk in Every Breast Research Session During National Meeting, NXT-41x Heads to FDA This Quarter, Fully Funded Through Launch

Aziyo Biologics (AZYO)Aziyo BiologicsFDA / regulatory

Infection is a Major Unmet Need in Plastic and Reconstructive Surgery: Infection risk was cited in all 11 breast research sessions at the American Society of Plastic Surgeons’ annual meeting, with serious infection rates reported as high as 23%. NXT-41x In Vivo Study Supports Planned Q4 2026 FDA

Related news

Aziyo Biologics

Drug-Eluting Biomatrix Company Elutia, formerly known as Aziyo Biologics, develops biologic matrices designed to support tissue repair while delivering antimicrobial protection at the surgical site. Antibiotic-Eluting Platform The company's biomatrix technology incorporates antibiotics into a biologic scaffold. The platform was first...

Recent company news

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States